FIELD: biotechnology; medicine.
SUBSTANCE: method of treating HER2-positive cancer that expresses SEMA4D in a subject is provided. The method includes intratumoral administration to a subject of a therapeutically effective amount of HER2 oncodriver-loaded dendritic cells, in combination with systemic administration of an effective amount of an anti-SEMA4D antibody or antigen-binding fragment thereof characterized by amino acid sequences of complementarity-determining regions (CDRs) with SEQ ID NO: 5–7, 8–10 and SEQ ID NO: 11–13, 14–16. The following is also proposed: the use of a combination of these dendritic cells loaded with the HER2 oncodriver and the specified anti-SEMA4D antibody or antigen-binding fragment for the treatment of HER2-positive cancer that expresses SEMA4D.
EFFECT: inventions provide effective treatment of HER2-positive cancer that expresses SEMA4D, in particular, regression of tumors both injected and not injected with HER2-loaded dendritic cells.
10 cl, 19 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| VECTOR, CO-EXPRESSING MOLECULES FOR VACCINATION AND COSTIMULATORY MOLECULES | 2016 |
|
RU2714157C2 |
| COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT | 2016 |
|
RU2733315C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| VIRUS VECTOR | 2020 |
|
RU2799418C1 |
| CD30XCD16 ANTIBODY COMBINATION FOR THERAPY WITH PD-1 ANTAGONIST | 2016 |
|
RU2761352C2 |
| METHOD FOR ACTIVATING CYTOTOXIC T-LYMPHOCYTES IN A POPULATION OF BLOOD MONONUCLEAR CELLS USING MEMBRANE VESICLES OBTAINED FROM GENETICALLY MODIFIED TUMOR CELLS OF M14 MELANOMA WITH OVEREXPRESSION OF INTERLEUKIN 2 | 2022 |
|
RU2790867C1 |
| COMPOSITIONS AND METHODS OF TREATING CANCER | 2016 |
|
RU2729396C2 |
